Alignment and Aperture Scan at the Fermilab Booster

The Fermilab booster has an intensity upgrade plan called the Proton Improvement plan (PIP). The flux throughput goal is 2E17 protons/hour, which is almost double the current operation at 1.1E17 protons/hour. The beam loss in the machine is going to be the source of issues. The booster accelerates beam from 400 MeV to 8 GeV and extracts to the Main Injector. Several percent of the beam is lost within 3 msec after the injection. The aperture at injection energy was measured and compared with the survey data. The magnets are going to be realigned in March 2012 in order to increase the aperture. The beam studies, analysis of the scan and alignment data, and the result of the magnet moves will be discussed in this paper.Comment: 3 pp. 3rd International Particle Accelerator Conference (IPAC 2012) 20-25 May 2012, New Orleans, Louisian

An experimentally robust technique for halo measurement using the IPM at the Fermilab Booster

We propose a model-independent quantity, $L/G$, to characterize non-Gaussian tails in beam profiles observed with the Fermilab Booster Ion Profile Monitor. This quantity can be considered a measure of beam halo in the Booster. We use beam dynamics and detector simulations to demonstrate that $L/G$ is superior to kurtosis as an experimental measurement of beam halo when realistic beam shapes, detector effects and uncertainties are taken into account. We include the rationale and method of calculation for $L/G$ in addition to results of the experimental studies in the Booster where we show that $L/G$ is a useful halo discriminator

Microwave-driven synthesis of bisphosphonate nanoparticles allows in vivo visualisation of atherosclerotic plaque

A fast and reproducible microwave-driven process has allowed us to synthesise neridronate-functionalised nanoparticles. Contrary to tradition, the phosphate groups decorate the outside layer of the particles providing Ca2+ binding properties in vitro and selective accumulation in vivo in the atheroma plaque. In vivo and ex vivo detection by T2-weighted MRI is demonstrated and validated by histology. The accumulation in the plaque takes place in less than one hour following the intravenous injection, which is particularly suitable for clinical applications

Cu-Doped Extremely Small Iron Oxide Nanoparticles with Large Longitudinal Relaxivity: One-Pot Synthesis and in Vivo Targeted Molecular Imaging

Synthesizing iron oxide nanoparticles for positive contrast in magnetic resonance imaging is the most promising approach to bring this nanomaterial back to the clinical field. The success of this approach depends on several aspects: the longitudinal relaxivity values, the complexity of the synthetic protocol, and the reproducibility of the synthesis. Here, we show our latest results on this goal. We have studied the effect of Cu doping on the physicochemical, magnetic, and relaxometric properties of iron oxide nanoparticles designed to provide positive contrast in magnetic resonance imaging. We have used a one-step, 10 min synthesis to produce nanoparticles with excellent colloidal stability. We have synthesized three different Cu-doped iron oxide nanoparticles showing modest to very large longitudinal relaxivity values. Finally, we have demonstrated the in vivo use of these kinds of nanoparticles both in angiography and targeted molecular imaging